Previous 10 | Next 10 |
Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, April 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC...
Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program PR Newswire TEL AVIV , Israel and BETHESDA, Md., April 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer r...
Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33 PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, March 31, 2021 /PRNewswire/--Cannabics Pharmaceuticals Inc. (OTCQB: CNBX)...
Cannabics Pharmaceuticals (CNBX) announces results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human colorectal cancer cells.Study results indicate a 35% prolonged survival rate in mice exp...
Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells PR Newswire TEL AVIV , Israel and BETHESDA, Md., March 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNB...
Mexico with 121 million citizens will likely legalize cannabis by April of this year opening the door to the largest population for potential customers; This will be a game-changing tipping point for legalization of cannabis around the world and especially throughout Latin America; ...
Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016 PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, Feb. 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB...
Cannabics Pharmaceuticals ([[CNBX]]) announces the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice.The final study results showed a significant and robust inhibitory effect on tum...
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/ -- Can...
Cannabics Pharma ([[CNBX]] +9.7%) has obtained positive interim results for its ongoing in-vivo study evaluating the efficacy of the company's RCC-33 for colorectal cancer in nude-mice.The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison ...
News, Short Squeeze, Breakout and More Instantly...
Cannabics Pharmaceuticals Inc Company Name:
CNBX Stock Symbol:
OTCMKTS Market:
Cannabics Pharmaceuticals Inc Website:
CNBX Pharmaceuticals Inc (CNBX) is expected to report for Q1 2003
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma PR Newswire REHOVOT, Israel and BETHESDA, MD , Nov. 8, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader i...
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy PR Newswire REHOVOT, Israel and BETHESDA, MD. , Oct. 18, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of...